AJNA BioSciences develops FDA-approved botanical drugs by utilizing a drug development platform that standardizes and characterizes plant and fungi species with established therapeutic histories. The company addresses the lack of reliable botanical pharmaceutical options by transforming naturally derived psychedelics, such as psilocybin, into clinically validated treatments.
Funding
$10.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The pharmaceutical industry lacks reliable botanical drug options due to challenges in standardizing and characterizing plant-derived compounds for FDA approval. Existing botanical medicines often lack rigorous clinical validation, creating a gap between patient demand for natural alternatives and physician advocacy for evidence-based treatments.
Solution
AJNA BioSciences addresses this gap by developing FDA-approved botanical drugs using a proprietary platform that standardizes and characterizes plant and fungi species with established therapeutic histories. The company focuses on transforming naturally derived compounds, including psychedelics, into clinically validated treatments. By applying modern chemistry, manufacturing, and controls (CMC) and scientific instrumentation, AJNA BioSciences characterizes and standardizes botanical raw materials to meet FDA standards. This approach streamlines the drug discovery process, mitigates late-stage clinical trial risk, and facilitates the commercialization of novel botanical pharmaceuticals. The company initiates FDA clinical trials to prove safety and efficacy, paving the way for multiple go-to-market strategies, including licensing, joint ventures, acquisitions, or complete vertical integration.
Target Audience
AJNA BioSciences targets individuals seeking botanical pharmaceutical options and physicians advocating for evidence-based natural treatments.
Features
- Drug development platform focused on botanical raw materials
- Specialization in plant and fungi species with a history of therapeutic use
- Application of modern CMC and scientific instrumentation to characterize and standardize botanical raw materials to FDA standards
- FDA clinical trials to prove safety and efficacy
- Focus on natural psychedelics, such as psilocybin
- Unique IP protection due to the intricate composition of botanical mixtures